| EMRYX | VEMIX | EMRYX / VEMIX | |
| Total Expense Ratio | 1.12 | 0.09 | 1,244% |
| Annual Report Gross Expense Ratio | 1.23 | 0.09 | 1,367% |
| Fund Existence | 16 years | 26 years | - |
| Gain YTD | 28.391 | 21.721 | 131% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 319M | 141B | 0% |
| Annual Yield % from dividends | 1.20 | 2.82 | 42% |
| Returns for 1 year | 25.87 | 20.22 | 128% |
| Returns for 3 years | 44.54 | 46.12 | 97% |
| Returns for 5 years | -10.01 | 20.62 | -49% |
| Returns for 10 years | 51.83 | 89.03 | 58% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IHE | 86.21 | 0.86 | +1.01% |
| iShares US Pharmaceuticals ETF | |||
| IWFL | 59.15 | 0.29 | +0.48% |
| ETRACS 2x Leveraged US Gr Fctr TR ETN | |||
| SCHF | 24.14 | 0.05 | +0.21% |
| Schwab International Equity ETF™ | |||
| FDTX | 41.24 | 0.08 | +0.19% |
| Fidelity Disruptive Technology ETF | |||
| XCNY | 27.98 | -0.05 | -0.19% |
| SPDR S&P Emerging Markets ex-China ETF | |||